Decreased expression of human papillomavirus E2 protein and transforming growth factor-β1 in human cervical neoplasia as an early marker in carcinogenesis

Journal of Surgical Oncology

Volumn 84, Issue 1, 2003, Pages 17-23

  Torng, Pao Ling ^a   Chan, Wing Yee ^a   Lin, Chin Tang ^a   Huang, Su Cheng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cervical intraepithelial neoplasia; Human papillomavirus; Transforming growth factor; Transforming growth factor receptor; Uterine cervix

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VIRUS E2 PROTEIN; VIRUS PROTEIN;

ARTICLE; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA-BINDING PROTEINS; FEMALE; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0043194050     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10273     Document Type: Article

References (46)

1. Liaw KL, Hsing AW, Chen CJ, et al.: Human papillomavirus and cervical neoplasia: A case-control study in Taiwan. Int J Cancer 1995;62:565-571.
2. zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
3. Dyson N, Howley PM, Munger K, et al.: The human papillomavirus-16 E7 oncoprotein is able to bind to retinoblastoma gene product. Science 1989;243:934-937.
4. Werness BA, Levine AJ, Howley PM: Association of human papilloma virus-16 and -18 E6 proteins with p53. Science 1990;248:76-79.
5. Turek LP, Smith EM: The genetic program of genital human papillomaviruses in infection and cancer. Obstet Gynecol Clin North Am 1996;23:735-758.
6. Dowhanick JJ, McBride AA, Howley PM: Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995;69:7791-7799.
7. Durst M, Kleinheinz A, Hotz M: The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumors. J Gen Vriol 1985;66:1515-1522.
8. Schwarz E, Freese UK, Gissmann L, et al.: Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-114.
9. Turek LP: The structure, function, and regulation of papilloma viral genes in infection and cervical cancer. Adv Virus Res 1994;44:305-306.
10. Maitland NJ, Conway S, Wilkinson NS, et al.: Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J Pathol 1998;186:275-280.
11. Stevenson M, Hudson LC, Burns JE, et al.: Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and viral DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 2000;81:1825-1832.
12. Kalantari M, Karlsen F, Kristensen G, et al.: Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 1998;17:146-153.
13. Braun L, Durst R, Mikumo R, et al.: Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor β1. Cancer Res 1990;50:7324-7332.
14. Shipley GD, Pittelkow MR, Wille JJ, et al.: Reversible inhibition of normal human prokeratinocyte proliferation by β transforming growth factor-growth inhibitor in serum-free medium. Cancer Res 1986;46:2068-2071.
15. Woodworth CD, Notario V, DiPaolo JA: Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990;64:4767-4775.
16. Braun L, Durst M, Mikumo R, et al.: Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor β: Implications for the control of papillomavirus infection. Mol Carcinog 1992;6:100-111.
17. De Geest K, Turyk ME, Hosken MI, et al.: Growth and differentiation of human papillomavirus type 31b-positive human cervical cell lines. Gynecol Oncol 1993;49:303-310.
18. Dagnino LJ, Pietenpol JA, Yang EY, et al.: Transforming growth factor regulation of keratinocyte growth. Recent Results Cancer Res 1993;128:15-29.
19. Chen J, de Vries EGE, Hollema H, et al.: Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer 1999;82:43-51.
20. Kang SH, Won K, Chung HW, et al.: Genetic integrity of transforming growth factor β (TGF-β) receptors in cervical carcinoma cell lines: Loss of growth sensitivity but conserved transcriptional response to TGF. Int J Cancer 1998;77:620-625.
21. Heldin CH, Miyazono K, ten Dijke P: TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390: 465-471.
22. Sanders CM, Stern PL, Maitland NJ: Characterization of human papillomavirus type 16 E2 protein and subdomains expressed in insect cells. Virology 1995;211:418-443.
23. Dellas A, Schultheiss E, Almendral AC, et al.: Assessment of EGFR and TGF-alpha expression in relationship to HPV status and Ki-67 distribution in cervical intraepithelial neoplasms. Int J Cancer 1996;69:165-169.
24. Ozbun MA, Meyers C: Transforming growth factor β1 induces differentiation in human papillomavirus-positive keratinocytes. J Virol 1996;70:5437-5446.
25. De Geest K, Bergman CA, Turyk ME, et al.: Differential response of cervical intraepithelial and cervical carcinoma cell lines to transforming growth factor-β1. Gynecol Oncol 1994;55:376-385.
26. Comerci JT, Runowicz CD, Flanders KC, et al.: Altered expression of transforming growth factor-β1 in cervical neoplasia as an early marker in carcinogenesis of the uterine cervix. Cancer 1996; 77:1107-1114.
27. El-Sherif AM, Seth R, Tighe PJ, et al.: Decreased synthesis and expression of TGF-β1, β2, and β3 in epithelium of HPV 16-positive cervical precancer: A study by microdissection, quantitative RT-PCR, and immunocytochemistry. J Pathol 2000;192: 494-451.
28. Shi WK, Ye QW, Bao LP: Biological characterization of a monoclonal antibody TB21 against TGF beta 1. Acta Biol Exp Sin 1993;26:141-150.
29. de Gruijl TD, Bontkes HJ, van den Muysenberg AJC, et al.: Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 1999;35:490-497.
30. Giannini SL, Ai-Saleh W, Piron H, et al.: Cytokine expression in squamous intraepithelial lesions of the uterine cervix: Implication for the generation of local immunosuppression. Clin Exp Immunol 1998;113:183-189.
31. Blanchette F, Day R, Laprise MH, et al.: TGF-beta 1 regulates gene expression of its own converting enzyme furin. J Clin Invest 1997;99:1974-1983.
32. Khalil N: Post translational activation of latent transforming growth factor beta (L-TGF-beta): Clinical implications. Histol Histopathol 2001;16:541-551.
33. Fraser D, Wakefield L, Phillips A: Independent regulation of transforming growth factor-β1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 2002; 161:1039-1040.
34. Kane CJ, Hebda PA, Mansbridge JN, et al.: Direct evidence for spatial and temporal regulation of transforming growth beta 1 expression during cutaneous wound healing. J Cell Physiol 1991;148:157-173.
35. Akhurst RJ, Balmain A: Genetic events and the role of TGFβ in epithelial tumor progression. J Pathol 1999;187:82-90.
36. Mi Y, Borger DR, Fernandes PR, et al.: Loss of transforming growth factor-β (TGF-β) receptor type I mediates TGF-β resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression. Virology 2000;270:408-416.
37. Schiffman MH, Bauer HM, Hoover RN, et al.: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasms. J Nat Cancer Inst 1993;85:958-964.
38. Das BC, Sharma JK, Gopalakrishna V, et al.: Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol 1992;73:2327-2336.
39. Baker CC, Phelps WC, Lindgren V, et al.: Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987;61:962-971.
40. Peitsaro P, Johansson B, Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40:886-891.
41. Nasiell K, Nasiell M, Vaclavinkova A: Behavior of moderate cervical dysplasia during long term follow-up. Obstet Gynecol 1983;61:609-614.
42. Nasiell K, Roger V, Nsiell M: Behavior of mild cervical dysplasia during long term follow-up. Obstet Gynecol 1986;67:665-669.
43. Durst H, Gallahan D, Jay G, et al.: Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papillomavirus type-16 and an activated ras oncogene. Virology 1989;173:767-771.
44. Tervahauta A, Syrjanen S, Yliskoski M, et al.: Expression of transforming growth factor-beta 1 and -beta 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix. Gynecol Oncol 1994;54:349-356.
45. Nishihara A, Hana JI, Imamura T, et al.: E1A inhibits transforming growth factor-β signaling through binding to Smad proteins. J Biol Chem 1999;274:28716-28723.
46. Bosch FX, Manos MM, MuOoz N, et al.: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.